menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Tracking a successful DLBCL assault in PhII, MorphoSys out to OK for MOR208

    PLATFORM

    Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report

    FIERCE PHARMA

    AbbVie`s Q4 sales miss the mark as cancer, hep C meds lag

    FIEREC PHARMA

    Conitec Approves Incorporation by SUS of AbbVie`s Drug for Chronic Hepatitis C

    PR NEWSWIRE

    EU Health Regulator Warns Some Hep C Drugs Could Reactivate Hep B

    REUTERS

    AbbVie Receives FDA Approval Of Viekria XR For The Treatment of Genotype 1 Chronic Hepatitis C

    FDA

    AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK

    PR NEWSWIRE

    Sanofi introduces new Priftin packaging to treat latent tuberculosis

    PR NEWS WIRE

    AbbVie Demonstrate Commitment to Hep C Patients with New Data on VIEKIRA PAK™

    PR NEWSWIRE

    NHS England stumps up £190m for hep C therapy

    PHARMATIMES

    Senator Asks Department of Veteran Affairs to Break Patents on Hepatitis C Drugs

    PATENT DOCS

    FDA Reaches Out to Minorities During Hepatitis Awareness Month

    FDA VOICE

    AbbVie moves closer to Japan`s crowded hep C field with priority review nod

    FIERCE PHARMA

    Medicaid Drug-Spending Hikes Rile Lawmakers, But There`s No End In Sight

    FIERCE PHARMA

    Gilead’s $1,000 Pill Is Hard for States to Swallow

    THE WALL STREET JOURNAL

    Heavyweight PBMs Mean Trouble For Big Pharma`s Pricey New Meds

    FIERCE PHARMA

    Gilead Warning of Hep C Patient Death on Heart Med Will Have “Zero Impact”

    PHARMALOT

    FDA Continues to Lead in Precision Medicine

    FDA VOICE

    Thomson Reuters Names Most Promising Drugs of 2015

    THOMSON REUTERS

    Big Pharma`s market cap stars of 2014: Lilly, AbbVie, AstraZeneca

    FIERCE PHARMA

    Drug spending surged 13% last year, with pricey hep C meds leading the charge

    FIERCE PHARMA

    Natco Joins Gilead’s Pact With Indian Companies For Sovaldi

    BLOOMBERG BUSINESS

    Bristol Hep C Drug Helps Cure 97 pct of HIV Coinfected Patients-Study

    REUTERS

    Gilead Looks Overseas to Guard Sovaldi Profits from Taxes

    FIERCE PHARMA

    Crown the New Drug Launch King: Gilead`s Harvoni Has Knocked Aside Sister Med Sovaldi

    FIERCE PHARMA MARKETING

    Say What? CVS Health Execs Figure PCSK9 Meds to Cost up to $150B

    FIERCE PHARMA

    Gilead Expects Big Increase in Europeans Treated with Hep C Drug

    REUTERS

    Gilead`s Pricey Sovaldi Lost a Patent in India. Now, Its EU Patent is Under Siege

    FIERCE PHARMA

    Humira Biosimilars Will Gut Abbvie`s Sales in 3 Years, Analyst Says

    FIERCE PHARMA

    Abbvie`s Exviera (Dasabuvir) Approved in Europe for Hepatitis C

    EMA

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.